POLICY STATEMENT

This policy describes how the Fred Hutchinson Cancer Research Center (Fred Hutch) Institutional Review Board (IRB) Chair (or designee) or the IRB Committee makes determinations for suspending or terminating research and the IRB process for determining which incidences require prompt reporting to Institutional Officials and applicable federal agencies.
DEFINITIONS

See *IRB Glossary of Terms and Acronyms* (050) for full definitions of the following:

**Institutional Official(s)**

**Noncompliance**

**Unanticipated Problems that Involve Risk to Research Participants or Others**

**Suspension of IRB Approval**

**Termination of IRB approval**

INDIVIDUALS AFFECTED BY THIS POLICY

The contents of this policy apply to Institutional Review Office (IRO) staff, IRB members, employees of Fred Hutch and investigators from other institutions who submit research studies to the Fred Hutch IRB for review and approval.

PRINCIPLES/OVERVIEW

It is the responsibility of the IRB to determine if any reports received from a study investigator and/or research staff warrant study suspension or termination and to promptly report such findings to the appropriate Institutional Officials and applicable federal agencies.

PROCEDURES

1. **Reporting Requirements**

   Reporting by Principal Investigators and Study Staff: Principal investigators and their study staff are required to report in accordance with IRO policies:

   - *Policy 1.9 Noncompliance* (029)
   - *Policy 2.6 Unanticipated Problems Involving Risks to Subjects or Others* (0224)

   Reporting by Others: Persons other than principal investigators and study staff reporting should report in accordance with *Policy 1.9 Noncompliance* (029).

2. **Type of Review**

   Once a report is made it will be reviewed with the Chair (or designee) of the IRB that approved the research. The IRB Chair or designee will utilize the *IRB Chair or Designee Report Checklist for Unanticipated Problems or Noncompliance* (074) in this review.

   The IRB Chair or designee, may also discuss the report with the IRO Director and/or Assistant Director and General Counsel, if appropriate. The Chair will determine the method of IRB review of the report based on the possible increase of risk to research participants, the welfare and safety of research participants; or, if data integrity of the study is affected due to continued noncompliance or an unanticipated problem which meets the criteria as defined above. The IRB Chair or designee is authorized to suspend or terminate the study in order to protect the rights and welfare of currently enrolled participants, including studies that have an exempt determination. The IRB Chair or designee will forward the report to be reviewed by the full IRB Committee, one of the following methods of review will be used:

   1. Regularly scheduled IRB meeting: The IRB will review the event at a regularly scheduled meeting if the event occurred before the meeting date. The IRB staff notifies the PI that the incident will be reviewed at the next scheduled IRB meeting.
2. **Emergency meeting:** An emergency meeting is a meeting that takes place outside the regularly scheduled IRB meeting dates. If review must take place immediately, an emergency meeting is scheduled. The PI will be notified that an emergency meeting will be scheduled.

3. **Actions and Decisions by Convened IRB**

The IRB Committee will be forwarded a copy of the *IRB Chair or Designee Report Checklist for Unanticipated Problems or Noncompliance* (074) and may make any of the following determinations:

- Require a response from the PI with a plan for corrective actions.
- Initiate audits of the active protocols involved.
- Require that research participants previously enrolled in the study be contacted and provided with additional information and/or re-consented.
- Require more frequent review of the study.
- Suspend or terminate the study.
- Freeze the sponsored research grant account.
- Determine that the data collected cannot be used for publication.
- Report to the sponsor, administrative officials, and governmental agencies, e.g., FDA, OHRP.
- Disqualify the PI from conducting research involving human research participants at Fred Hutch.

4. **Suspensions or Termination of IRB Approval**

If the committee determines the previously approved research is not being conducted in accordance with the IRB's requirements or that the research encountered new findings or new information that may have changed the risks-benefits assessment, the IRB may suspend or terminate IRB approval of the research, including studies that have an exempt determination.1

**Actions taken when Study Approval is Suspended by the IRB (if applicable):**

- Accrual of new research participants into the study will cease
- Currently enrolled research participants will be notified of the Suspension.
- The PI will be informed via a result letter if the IRB requires or permits follow-up for safety considerations.
- If the IRB requires/permits follow-up with research participants for safety considerations, adverse events should be reported to the IRB and sponsor (if applicable).
- If the IRB requires the withdrawal of research participants they will consider the rights and welfare of research participants.

**Actions taken when Study Approval is Terminated by the IRB:**

- Currently enrolled research participants are notified of the termination.
- Procedures for withdrawal of research participants consider the rights and welfare of research participants.
- The research participants are informed if the IRB requires or permits follow-up for safety considerations.

---

1 HHS: 45 CFR 46.113; FDA: 21 CFR 56.113
• If the IRB requires/permits follow-up with research participants for safety considerations, adverse events should be reported to the IRB and sponsor (if applicable).

Any suspension or termination of IRB approval shall include a statement of the reasons for the IRB's action and shall be reported within 48 hours of the suspension or termination to the PI. Any suspension or termination of IRB approval will be reported to appropriate institutional and government officials as detailed in IRB Policy 2.8 IRB Requirements for Reporting to Institutional Official and External Officials (021). If the study is a UW Consortium study, the UW HSD will be notified.?

In the case of suspension, the PI may request, in writing with appropriate rationale, that the IRB permit currently enrolled research participants to receive treatment and/or intervention based on their health needs.

The PI may request to re-open a previously suspended or terminated study and must submit their request in writing to the IRO. Such requests will receive full IRB review upon receipt.

SUPPORTING DOCUMENTS

IRB Policy 1.9 Noncompliance (029)
IRB Policy 2.6 Unanticipated Problems Involving Risks to Subjects or Others (0224)
IRB Policy 2.8 IRB Requirements for Reporting to Institutional and External Officials (021)
IRB Chair or Designee Report Checklist for Unanticipated Problems or Noncompliance (074)
IRB Glossary of Terms and Acronyms (050)

REFERENCES

45 CFR 46.108
45 CFR 46.113
21 CFR 56.108
21 CFR 56.113

OHRP Guidance on Reporting and Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events January 15, 2007

Office of Human Research Protections (OHRP) Compliance Activities: Common Findings and Guidance #71 (a)-(c) and (m)-(o), and #72

Food and Drug Administration (FDA) Information Sheets: Continuing Review After Study Approval

---

2 HHS: 45 CFR 46.108(a)(4)(ii); FDA: 21 CFR 56.108(b)(3)